Serum monitoring of antipsychotic drug levels during concomitant administration of sertraline and antipsychotic medication

Canadian Journal of Psychiatry

Volumn 51, Issue 11, 2006, Pages 715-718

  Pierson, Kathleen ^a   Addington, Donald ^a   Addington, Jean ^b   Patten, Scott ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Antipsychotic agents; Depression; Drug interactions; Schizophrenia; Sertraline

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; PIPOTIAZINE; PLACEBO; RISPERIDONE; SERTRALINE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL DECANOATE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG BLOOD LEVEL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 33750246908     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674370605101109     Document Type: Article

References (16)

1. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991;36:239-45.
2. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-20.
3. Addington D, Addington J, Patten S, Remington G, Moamai J, Labelle A, and others. Double-blind, placebo controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia. J Clin Psychopharmacol 2002;22(1):20-5.
4. Addington D, Addington J, Maticka-Tyndale E. Reliability and validity of a depression rating scale for schizophrenics. A structured interview guide for the Hamilton Depression Rating Scale. Schizophr Res 1992;6:201-8.
5. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
6. Chouinard G, Ross-Chouinard A, Annable L. The extrapyramidal symptom rating scale. Can J Neurol Sci 1980;7:233.
7. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatr 1960;23:56-62.
8. Riedel M, Schwarz MJ, Strassnig M, Spellmann I, Muller-Arends A, Weber K, and others. Risperidone plasma levels, clinical response and side effects. Eur Arch Psychiatry Clin Neurosci 2005;255:261-8.
9. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking and comedication. Ther Drug Monitor 2003;25:46-53.
10. Rey MJ, Schulz P, Costa C, Dick P, Tissot R. Guidelines for the dosage of neuroleptics. Int Clin Psychopharmacol 1989;4:95-104.
11. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-7.
12. Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry. 2004;161:1324-33.
13. Spina E, D'Arrigo C, Migliardi G, Morgante L, Zoccali R, Ancione M, and others. Plasma risperidone concentrations during combined treatment with sertraline. Ther Drug Monit 2004;26:386-90.
14. Weigmann H, Gerek S, Zeisig A, Muller M, Hartter S, Hiemke C. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 2001;23:410-3.
15. Spina E, Avenoso A, Salemi M, Facciola G, Scordo MG, Ancione M, and others. Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. Pharmacopsychiatry 2000;33:213-7.
16. Lee MS, Han CS, You YW, Kim SH. Co-administration of sertraline and haloperidol. Psychiatry Clin Neurosci 1998;52 Suppl:S193-S198.